BUZZ-杰富瑞认为澳大利亚 CSL 公司每股收益下降

Reuters03-26

((自动化翻译由路透提供，请见免责声明 ))

3月25日 - ** Jefferies 分析师认为，CSL Vifor 将受到 Viatris 可能于 24 财年下半年在美国市场推出仿制 Venofer(铁蔗糖注射液) 的影响。

** 券商维持 CSL 338.50 澳元/股的目标价和 "买入 "评级

** 杰富瑞预计CSL Vifor在美国销售Venofer活性药物成分的分销商利润率将低于在欧盟销售该产品的利润率。

** 券商认为 CSL 26 财年的每股收益将下降 0.8

** 16位分析师中有11位将该股评为 "买入 "或更高评级，4位评为 "持有"，1位评为 "卖出"；他们的PT中值为310.00澳元--LSEG数据

** 截至上次收盘，该股今年下跌了 1

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2422141524?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-03-26 02:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2422141524","market":null,"top_or_hot":-1,"title":"BUZZ-杰富瑞认为澳大利亚 CSL 公司每股收益下降","media":"Reuters","content":"<html><body><p>((自动化翻译由路透提供，请见免责声明 ))</p><p>    3月25日 - ** Jefferies 分析师认为，CSL    Vifor 将受到 Viatris    可能于 24 财年下半年在美国市场推出仿制 Venofer(铁蔗糖注射液) 的影响。</p><p>** 券商维持 CSL 338.50 澳元/股的目标价和 \"买入 \"评级</p><p>** <a href=\"https://laohu8.com/S/JEF\">杰富瑞</a>预计CSL Vifor在美国销售Venofer活性药物成分的分销商利润率将低于在欧盟销售该产品的利润率。</p><p>** 券商认为 CSL 26 财年的每股收益将下降 0.8</p><p>** 16位分析师中有11位将该股评为 \"买入 \"或更高评级，4位评为 \"持有\"，1位评为 \"卖出\"；他们的PT中值为310.00澳元--LSEG数据</p><p>** 截至上次收盘，该股今年下跌了 1 </p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-杰富瑞认为澳大利亚 CSL 公司每股收益下降</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-杰富瑞认为澳大利亚 CSL 公司每股收益下降\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-03-26 02:32 北京时间&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>((自动化翻译由路透提供，请见免责声明 ))    3月25日 - ** Jefferies 分析师认为，CSL    Vifor 将受到 Viatris    可能于 24 财年下半年在美国市场推出仿制 Venofer(铁蔗糖注射液) 的影响。** 券商维持 CSL 338.50 澳元/股的目标价和 \"买入 \"评级** 杰富瑞预计CSL Vifor在美国销售Venofer活性药物成分的分销商...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VTRS","symbol_name":"Viatris Inc.","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2422141524","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2422141524","pubTimestamp":1711391569,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"    3月25日 - ** Jefferies 分析师认为，CSL    Vifor 将受到 Viatris    可能于 24 财年下半年在美国市场推出仿制 Venofer 的影响。** 券商维持 CSL 338.50 澳元/股的目标价和 \"买入 \"评级** 杰富瑞预计CSL Vifor在美国销售Venofer活性药物成分的分销商利润率将低于在欧盟销售该产品的利润率。** 券商认为 CSL 26 财年的每股收益将下降 0.8** 16位分析师中有11位将该股评为 \"买入 \"或更高评级，4位评为 \"持有\"，1位评为 \"卖出\"；他们的PT中值为310.00澳元--LSEG数据** 截至上次收盘，该股今年下跌了 1","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"VTRS":"Viatris Inc.","BK7501":"新冠治疗股","LU2087621335.USD":"ALLSPRING GLOBAL FACTOR ENHANCED EQUITY \"A\" (USD) ACC","BK7508":"医药生物股","CSL.AU":"CSL LIMITED","BK4585":"ETF&股票定投概念","BK4588":"碎股","BK4583":"猴痘概念","BK7067":"生物科技","BK4007":"制药","LU1839511570.USD":"WELLS FARGO GLOBAL FACTOR ENHANCED EQUITY \"I\" (USD) ACC","BK7511":"ESG概念"},"translate_title":"BUZZ-Jefferies thinks CSL Australia's earnings per share fell","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CSL.AU":1,"VTRS":0.9},"content_text":"((自动化翻译由路透提供，请见免责声明 ))    3月25日 - ** Jefferies 分析师认为，CSL    Vifor 将受到 Viatris    可能于 24 财年下半年在美国市场推出仿制 Venofer(铁蔗糖注射液) 的影响。** 券商维持 CSL 338.50 澳元/股的目标价和 \"买入 \"评级** 杰富瑞预计CSL Vifor在美国销售Venofer活性药物成分的分销商利润率将低于在欧盟销售该产品的利润率。** 券商认为 CSL 26 财年的每股收益将下降 0.8** 16位分析师中有11位将该股评为 \"买入 \"或更高评级，4位评为 \"持有\"，1位评为 \"卖出\"；他们的PT中值为310.00澳元--LSEG数据** 截至上次收盘，该股今年下跌了 1","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2422141524"}